Stuart A. McMillan

I'll research this attorney before drafting.

Professional Summary — Stuart A. McMillan (Bowles Rice LLP)

Specialty / focus areas. McMillan is a general commercial and civil litigator, not a patent specialist. His Bowles Rice practice description centers on civil and appellate litigation, products liability defense, insurance coverage and bad-faith, financial services, oil and gas, mass/toxic torts, and class-action defense; patent litigation is not listed among his practice areas. His only tracked patent appearance is in Regeneron Pharmaceuticals, Inc. v. Amgen Inc. (N.D. W. Va.), a biologics/BPCIA dispute — specifically the aflibercept (EYELEA®) patent litigation consolidated as In re Aflibercept Patent Litigation, MDL No. 1:24-md-3103-TSK-JPM (associated with Case Nos. 1:24-cv-39-TSK and 1:25-cv-74-TSK). So the technology exposure visible in the record is pharmaceutical/biologics and follow-on biosimilar (Amgen's PAVBLU®/ABP 938), not Wi-Fi, software, or mechanical arts.

Side preference. The tracked data show one defendant-side appearance and no plaintiff-side appearances. That is consistent with his broader defense-oriented profile (products liability defense, insurance defense, class-action defense) and with the Regeneron matter, where he appears for Amgen as defendant. There is no record of NPE/PAE-side plaintiff work. Extrapolating a "one-sided" practice from a single tracked case would be over-reading, but nothing in the data or public record suggests plaintiff-side patent prosecution.

Firm context. McMillan has been a partner at Bowles Rice LLP (Charleston, West Virginia) since 1993 and has spent his career there; no prior firms appear in the public record. He serves as the firm's General Counsel, sits on its Executive Committee, formerly chaired its Litigation Department, and leads its Mass & Toxic Torts practice group. Bowles Rice acts as local counsel for Amgen in the MDL alongside national counsel, which matches the "local counsel" role in the tracked data. His co-counsel of record in the MDL is Bowles Rice's Kaitlyn N. McKitrick.

Notable cases / outcomes. The Regeneron matter is the one patent case on his docket. Court filings show him signing stipulations and case-management papers for Amgen in the aflibercept MDL, including a January 2026 stipulation of dismissal narrowing Regeneron's asserted patents against the 2 mg product, and the MDL's ongoing claim-construction schedule (claim-construction briefing ran August–September 2026, with Amgen as sole remaining defendant). The district court denied Regeneron's motion for a preliminary injunction against Amgen (addresses, among other things, infringement under the doctrine of equivalents); I have not verified a Federal Circuit disposition attributable to McMillan's role, and he is not listed among the appellate counsel of record in the materials reviewed. His reported trial results otherwise are non-patent — a federal jury verdict in a commercial dispute (Kinsale Insurance v. JDBC Holdings), a defense verdict/class dismissal in a TCPA class action (Mey v. All Access Telecom), and a multimillion-dollar healthcare fraud judgment for Highmark. PTAB/IPR: no record of him appearing in IPR, PGR, or other PTAB proceedings was found.

Bar / education. J.D., West Virginia University College of Law (1993); B.A., Vanderbilt University (1988). Admitted in West Virginia (1993), the U.S. District Courts for the Northern and Southern Districts of West Virginia, and the U.S. Court of Appeals for the Fourth Circuit. No Federal Circuit bar admission was found.

Caveat: This summary rests on a single tracked patent case, and that appearance is a local-counsel role. Treat the patent-specific portion of this profile as narrow and case-specific rather than as evidence of a patent litigation practice.